Ionis Pharmaceuticals discovers/develops RNA-targeted therapeutics using its proprietary antisense oligonucleotide technology. Its antisense medicines have been developed/are being developed to treat neurological, cardiovascular and specialty rare diseases.
| Revenue (Most Recent Fiscal Year) | $944.00M |
| Net Income (Most Recent Fiscal Year) | $-381.39M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 4.68 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 11.38 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -56.64% |
| Net Margin (Trailing 12 Months) | -56.98% |
| Return on Equity (Trailing 12 Months) | -120.62% |
| Return on Assets (Trailing 12 Months) | -16.99% |
| Current Ratio (Most Recent Fiscal Quarter) | 5.43 |
| Quick Ratio (Most Recent Fiscal Quarter) | 5.36 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 3.42 |
| Inventory Turnover (Trailing 12 Months) | 0.72 |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.36 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.66 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.38 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.32 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 166.54M |
| Free Float | 163.53M |
| Market Capitalization | $4.49B |
| Average Volume (Last 20 Days) | 4.80M |
| Beta (Past 60 Months) | 0.43 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 1.81% |
| Percentage Held By Institutions (Latest 13F Reports) | 93.86% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |